As shown in Fig. 7B, the injection regimen of ANP‐HA‐GNPs in treatment setting II did not significantly reduce RB tumor growth in comparison to the controls, whereas topical administration of ANP‐HA‐GNPs eye drops led to a significant tumor reduction after the first treatment cycle at Day 17 and further, not yet significant, reduced tumor growth upon Day 24 (Fig. 7C). This evidence concerns the gene NPPA and retinoblastoma.